Parasitic diseases have an enormous health, social and economic impact and are a
particular problem in tropical regions of the world. Diseases caused by protozoa and …

Research in visceral leishmaniasis in the last decade has been focused on how better to
use the existing medicines as monotherapy or in combination. Systematic research by …

Introduction: Leishmaniasis broadly manifests as visceral leishmaniasis (VL), cutaneous
leishmaniasis (CL) and mucocutaneous leishmaniasis. The treatment of leishmaniasis is …

The chemotherapy currently available for leishmaniasis is far from satisfactory. Resistance to
the pentavalent antimonials, which have been the recommended drugs for the treatment of …

Introduction: Leishmaniasis is a vector-borne neglected tropical disease which manifests as
visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucocutaneous …

Introduction: Leishmaniasis broadly manifests as visceral leishmaniasis (VL), cutaneous
leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL). The treatment of VL is …

Visceral leishmaniasis or Kala-azar is a vector-borne disease caused by an intracellular
parasite of the genus leishmania. In India, Amphotericin B (AmB) is a first-line medication for …

The treatment options of leishmaniasis are limited and far from satisfactory. For more than 60
years, treatment of leishmaniasis has centered around pentavalent antimonials (Sb v) …

Visceral leishmaniasis (VL) is a serious parasitic disease causing considerable mortality
and major disability in the Indian subcontinent. It is most neglected tropical disease …

Leishmaniasis, in its variety of visceral (VL), cutaneous (CL) and mucocutaneous (MCL)
forms, directly affects about 2 million people per annum, with approximately 350 million …